Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
Publication
, Journal Article
Shahid, I; Khan, MS; Sohail, A; Khan, SU; Greene, SJ; Fudim, M; Michos, ED
Published in: JAMA Netw Open
February 1, 2022
This cross-sectional study evaluates the representation of women as authors of pivotal trials of novel cardiovascular drugs approved by the US Food and Drug Administration between 2008 and 2020.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA Netw Open
DOI
EISSN
2574-3805
Publication Date
February 1, 2022
Volume
5
Issue
2
Start / End Page
e220035
Location
United States
Related Subject Headings
- Women
- United States Food and Drug Administration
- United States
- Sex Distribution
- Male
- Humans
- Female
- Drug Approval
- Cross-Sectional Studies
- Clinical Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Shahid, I., Khan, M. S., Sohail, A., Khan, S. U., Greene, S. J., Fudim, M., & Michos, E. D. (2022). Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. JAMA Netw Open, 5(2), e220035. https://doi.org/10.1001/jamanetworkopen.2022.0035
Shahid, Izza, Muhammad Shahzeb Khan, Aruba Sohail, Safi U. Khan, Stephen J. Greene, Marat Fudim, and Erin D. Michos. “Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.” JAMA Netw Open 5, no. 2 (February 1, 2022): e220035. https://doi.org/10.1001/jamanetworkopen.2022.0035.
Shahid I, Khan MS, Sohail A, Khan SU, Greene SJ, Fudim M, et al. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. JAMA Netw Open. 2022 Feb 1;5(2):e220035.
Shahid, Izza, et al. “Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.” JAMA Netw Open, vol. 5, no. 2, Feb. 2022, p. e220035. Pubmed, doi:10.1001/jamanetworkopen.2022.0035.
Shahid I, Khan MS, Sohail A, Khan SU, Greene SJ, Fudim M, Michos ED. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. JAMA Netw Open. 2022 Feb 1;5(2):e220035.
Published In
JAMA Netw Open
DOI
EISSN
2574-3805
Publication Date
February 1, 2022
Volume
5
Issue
2
Start / End Page
e220035
Location
United States
Related Subject Headings
- Women
- United States Food and Drug Administration
- United States
- Sex Distribution
- Male
- Humans
- Female
- Drug Approval
- Cross-Sectional Studies
- Clinical Trials as Topic